Imaging Findings in Children Presenting with CNS Nelarabine Toxicity

References

1. 1.↵
   1. Gandhi V,
   2. Keating MJ,
   3. Bate G, et al

   . Nelarabine. Nat Rev Drug Discov 2006;5:17–18 doi:10.1038/nrd1933 pmid:16485343

   CrossRefPubMed
2. 2.↵
   1. Teachey DT,
   2. O’Connor D

   . How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 2020;135:159–66 doi:10.1182/blood.2019001557 pmid:31738819

   CrossRefPubMed
3. 3.↵
   1. Berg SL,
   2. Blaney SM,
   3. Devidas M, et al

   ; Children’s Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 2005;23:3376–82 doi:10.1200/JCO.2005.03.426 pmid:15908649

   Abstract/FREE Full Text
4. 4.↵
   1. DeAngelo DJ,
   2. Yu D,
   3. Johnson JL, et al

   . Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B Study 19801. Blood 2007;109:5136–42 doi:10.1182/blood-2006-11-056754 pmid:17344466

   Abstract/FREE Full Text
5. 5.↵
   1. Dunsmore KP,
   2. Winter SS,
   3. Devidas M, et al

   . Children’s Oncology Group AALL0434: a Phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 2020;38:3282–93 doi:10.1200/JCO.20.00256 pmid:32813610

   CrossRefPubMed
6. 6.↵
   1. Kuhlen M,
   2. Bleckmann K,
   3. Moricke A, et al

   . Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol 2017;179:272–83 doi:10.1111/bjh.14877 pmid:28771662

   CrossRefPubMed
7. 7.↵
   1. Schiff D,
   2. Wen PY,
   3. van den Bent MJ

   . Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009;6:596–603 doi:10.1038/nrclinonc.2009.128 pmid:19707193

   CrossRefPubMed
8. 8.↵
   1. Madhavan AA,
   2. Carr CM,
   3. Alkhateeb H, et al

   . Nelarabine-induced myelotoxicity. Neurology 2021;96:175–76 doi:10.1212/WNL.0000000000011343 pmid:33310877

   CrossRefPubMed
9. 9.↵
   1. Lalayanni C,
   2. Baldoumi E,
   3. Papayiannopoulos S, et al

   . Nelarabine-associated reversible Guillain-Barre-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma. Curr Probl Cancer 2017;41:138–43 doi:10.1016/j.currproblcancer.2016.11.005 pmid:28169005

   CrossRefPubMed
10. 10.↵
    1. Kanayama T,
    2. Imamura T,
    3. Nakagawa N, et al

    . Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity. Pediatr Int 2017;59:843–45 doi:10.1111/ped.13303 pmid:28745456

    CrossRefPubMed
11. 11.↵
    1. Ewins K,
    2. Malone A,
    3. Phelan E, et al

    . Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history? Br J Haematol 2017;179:294–97 doi:10.1111/bjh.14921 pmid:28961308

    CrossRefPubMed
12. 12.↵
    1. Dua SG,
    2. Jhaveri MD

    . MR imaging in nelarabine-induced myelopathy. J Clin Neurosci 2016;29:205–06 doi:10.1016/j.jocn.2015.12.014 pmid:26899359

    CrossRefPubMed
13. 13.↵
    1. Hartz B,
    2. Lobel U,
    3. Hagel C, et al

    . Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am J Hematol 2013;88:1096–97 doi:10.1002/ajh.23550 pmid:23873785

    CrossRefPubMed
14. 14.↵
    1. Gollard RP,
    2. Selco S

    . Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia. J Clin Oncol 2013;31:e327–31 doi:10.1200/JCO.2012.45.4728 pmid:23715575

    FREE Full Text
15. 15.↵
    1. Papayannidis C,
    2. Iacobucci I,
    3. Abbenante MC, et al

    . Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol 2010;85:608 doi:10.1002/ajh.21719 pmid:20658590

    CrossRefPubMed
16. 16.↵
    1. Alberti P,
    2. Parma M,
    3. Pioltelli P, et al

    . Severe, reversible nelarabine-induced neuropathy and myelopathy. J Peripher Nerv Syst 2016;21:154–56 doi:10.1111/jns.12173 pmid:27117493

    CrossRefPubMed
17. 17.↵
    1. Dunsmore KP,
    2. Devidas M,
    3. Linda SB, et al

    . Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol 2012;30:2753–59 doi:10.1200/JCO.2011.40.8724 pmid:22734022

    Abstract/FREE Full Text
18. 18.↵
    1. Eaton A,
    2. Iasonos A,
    3. Gounder MM, et al

    . Toxicity attribution in Phase I trials: evaluating the effect of dose on the frequency of related and unrelated toxicities. Clin Cancer Res 2016;22:553–59 doi:10.1158/1078-0432.CCR-15-0339 pmid:26324741

    Abstract/FREE Full Text
19. 19.↵
    National Cancer Institute. NCI Guidelines for Investigators: Adverse Event Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/aeguidelines.pdf. Accessed June 29, 2022
20. 20.↵
    National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed July 26, 2022
21. 21.↵
    1. Le-Rademacher J,
    2. Hillman SL,
    3. Meyers J, et al

    . Statistical controversies in clinical research: value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol 2017;28:1183–90 doi:10.1093/annonc/mdx043 pmid:28184420

    CrossRefPubMed
22. 22.↵
    1. Nachman J,
    2. Sather HN,
    3. Gaynon PS, et al

    . Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. J Clin Oncol 1997;15:2222–30 doi:10.1200/JCO.1997.15.6.2222 pmid:9196134

    Abstract/FREE Full Text
23. 23.↵
    1. Commander LA,
    2. Seif AE,
    3. Insogna IG, et al

    . Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol 2010;150:345–51 doi:10.1111/j.1365-2141.2010.08236.x pmid:20528871

    CrossRefPubMed
24. 24.↵
    1. Arrillaga-Romany IC,
    2. Dietrich J

    . Imaging findings in cancer therapy-associated neurotoxicity. Semin Neurol 2012;32:476–86 doi:10.1055/s-0032-1331817 pmid:23361490

    CrossRefPubMed
25. 25.↵
    1. Iyer RS,
    2. Chaturvedi A,
    3. Pruthi S, et al

    . Medication neurotoxicity in children. Pediatr Radiol 2011;41:1455–64 doi:10.1007/s00247-011-2191-3 pmid:21785849

    CrossRefPubMed
26. 26.↵
    1. Tan AP

    . CAR-T cell therapy-related neurotoxicity in pediatric acute lymphoblastic leukemia: spectrum of imaging findings. Pediatr Neurol 2020;111:51–58 doi:10.1016/j.pediatrneurol.2020.06.014 pmid:32951662

    CrossRefPubMed
27. 27.↵
    1. Rossi A,
    2. Morana G,
    3. Gandolfo C, et al

    . Neuroradiology of chemotherapeutic: neurotoxicity in children. Neuroradiol J 2010;23:183–90 doi:10.1177/197140091002300206 pmid:24148536

    CrossRefPubMed
28. 28.↵
    1. Kontzialis M,
    2. Huisman T

    . Toxic-metabolic neurologic disorders in children: a neuroimaging review. J Neuroimaging 2018;28:587–95 doi:10.1111/jon.12551 pmid:30066477

    CrossRefPubMed
29. 29.↵
    1. Vazquez E,
    2. Delgado I,
    3. Sanchez-Montanez A, et al

    . Side effects of oncologic therapies in the pediatric central nervous system: update on neuroimaging findings. Radiographics 2011;31:1123–39 doi:10.1148/rg.314105180 pmid:21768243

    CrossRefPubMed
30. 30.↵
    1. Rossi Espagnet MC,
    2. Pasquini L,
    3. Napolitano A, et al

    . Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature. Pediatr Radiol 2017;47:633–48 doi:10.1007/s00247-016-3750-4 pmid:27933410

    CrossRefPubMed
31. 31.↵
    1. Stone JB,
    2. DeAngelis LM

    . Cancer-treatment-induced neurotoxicity–focus on newer treatments. Nat Rev Clin Oncol 2016;13:92–105 doi:10.1038/nrclinonc.2015.152 pmid:26391778

    CrossRefPubMed
32. 32.↵
    1. Riley KJ,
    2. O’Neill DP,
    3. Kralik SF

    . Subcortical U-fibers: signposts to the diagnosis of white matter disease. Neurographics 2018;8:234–43 doi:10.3174/ng.1700048

    CrossRef
33. 33.↵
    1. Saremi F,
    2. Helmy M,
    3. Farzin S, et al

    . MRI of cranial nerve enhancement. AJR Am J Roentgenol 2005;185:1487–97 doi:10.2214/AJR.04.1518 pmid:16304002

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Magge RS,
    2. DeAngelis LM

    . The double-edged sword: neurotoxicity of chemotherapy. Blood Rev 2015;29:93–100 doi:10.1016/j.blre.2014.09.012 pmid:25445718

    CrossRefPubMed
35. 35.↵
    1. Bhojwani D,
    2. Sabin ND,
    3. Pei D, et al

    . Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014;32:949–59 doi:10.1200/JCO.2013.53.0808 pmid:24550419

    Abstract/FREE Full Text